A Retrospective Cohort Study of Herbal Medicines Use during Pregnancy: Prevalence, Adverse Reactions, and Newborn Outcomes
-
Kosar Raoufinejad
,
Kheirollah Gholami
,
Mohammadreza Javadi
,
Mehdi Rajabi
,
Hassan Torkamandi
,
Ashraf Moeini
,
Niayesh Mohebbi
Abstract
This study aimed to investigate the herbal medicines use prevalence and adverse drug reactions (ADRs) during pregnancy as well as the probable effects on newborn outcomes. Postpartum women with a live singleton infant were eligible if declared consent before discharge. Data was collected retrospectively by face-to-face interviews. Generally, 400 pairs of mother/infant were recruited. At least one herbal medicine was used by 325/400 (81.3%) women. Peppermint, frankincense, flixweed, olive oil, and cinnamon were the most common herbs. Overall, 26 ADRs were reported by 19/325 (5.8%) women. Gastrointestinal complaints were the most frequent herbal ADRs (18/26, 69.2%). Gestational age, Apgar scores, birthweight, complications, and malformations of newborns were similar between groups. In conclusion, herbal medicines were highly used by pregnant women, while they did not affect newborn outcomes either positively or adversely. Despite low frequency rate of herbal ADRs during pregnancy, their safety, efficacy, interactions, and potential risks need further studies.
Bruno LO, Simoes RS, de Jesus Simoes M, Girao M, Grundmann O. Pregnancy and herbal medicines: an unnecessary risk for women's health - a narrative review. Phytother Res 2018;32:796-810.
Farah MH, Edwards R, Lindquist M, Leon C, Shaw D. International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Saf 2000;9:105-112.
Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, Phillips RS. Heavy metal content of ayurvedic herbal medicine products. JAMA 2004;292:2868-2873.
Barnes J. Pharmacovigilance of herbal medicines. Drug Saf 2003;26:829-851.
WHO. General guidelines for methodologies on research and evaluation of traditional medicine. WHO 2000. [Access date: Feb 12, 2019]. http://apps.who.int/medicinedocs/pdf/whozip42e/whozip42e.pdf.
IFDA. List of registered natural/herbal preparations. Iranian Ministry of Health and Medical Education, Food and Drug Administration 2019. [Access date: Feb 6, 2019]. http://www.fda.gov.ir/item/1886.
WHOCC. Anatomical therapeutic chemical (ATC) classification system. WHOCC 2019. [Access date: Feb 6, 2019]. http://www.whocc.no/atc_ddd_index/.
WHO. International statistical classification of diseases and related health problems 10th revision. WHO 2010. [Access date: Feb 12, 2019]. http://apps.who.int/classifications/icd10/browse/2010/en.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-1259.
MedDRA. Introductory guide MedDRA version 21.1. ICH 2018. [Access date: Feb 13, 2019]. https://www.meddra.org/sites/default/files/guidance/file/intguide_21_1_english.pdf.
WHO–UMC. The use of the WHO-UMC system for standardised case causality assessment. UMC 2000. [Access date: Jul 25, 2019]. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm 1992;49:2229-2232.
FDA. What is a serious adverse event? FDA 2016. [Access date: Jul 25, 2019]. http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm.
WHO. Medicines: safety of medicines - adverse drug reactions. WHO 2008. [Access date: Jul 25, 2019]. http://www.who.int/mediacentre/factsheets/fs293/en/index.html.
Cuzzolin L, Francini-Pesenti F, Verlato G, Joppi M, Baldelli P, Benoni G. Use of herbal products among 392 Italian pregnant women: focus on pregnancy outcome. Pharmacoepidemiol Drug Saf 2010;19:1151-1158.
Nordeng H, Havnen GC. Use of herbal drugs in pregnancy: a survey among 400 Norwegian women. Pharmacoepidemiol Drug Saf 2004;13:371-380.
Munoz Balbontin Y, Stewart D, Shetty A, Fitton CA, McLay JS. Herbal medicinal product use during pregnancy and the postnatal period: a systematic review. Obstet Gynecol 2019;133:920-932.
John LJ, Shantakumari N. Herbal medicines use during pregnancy: a review from the Middle East. Oman Med J 2015;30:229-236.
Nordeng H, Bayne K, Havnen GC, Paulsen BS. Use of herbal drugs during pregnancy among 600 Norwegian women in relation to concurrent use of conventional drugs and pregnancy outcome. Complement Ther Clin Pract 2011;17:147-151.
WebMD. Vitamins and supplements center. WebMD [Access date: Jul 21, 2019]. http://www.webmd.com/vitamins-supplements/.
Drugs.com. Drug information online: natural products. Wolters Kluwer Health [Access date: Jul 21, 2019]. http://www.drugs.com/npp/.
MedlinePlus. Herbs and supplements NIH [Access date: Jul 21, 2019]. http://www.nlm.nih.gov/medlineplus/druginfo/herb_All.html.
WHO. WHO monographs on selected medicinal plants. WHO [Access date: Jul 21, 2019]. http://apps.who.int/medicinedocs/en/d/Js2200e/.
Ernst E. Herbal medicinal products during pregnancy: are they safe? BJOG-Int J Obstet Gy 2002;109:227-235.
Kam PC, Barnett DW, Douglas ID. Herbal medicines and pregnancy: a narrative review and anaesthetic considerations. Anaesth Intensive Care 2019;47:226-234.
Kennedy DA, Lupattelli A, Koren G, Nordeng H. Safety classification of herbal medicines used in pregnancy in a multinational study. BMC Complement Altern Med 2016;16:102-102.
Holst L, Wright D, Haavik S, Nordeng H. The use and the user of herbal remedies during pregnancy. J Altern Complement Med 2009;15:787-792.
| Files | ||
| Issue | Vol 5, No 2, 2020 | |
| Section | Research Article(s) | |
| DOI | https://doi.org/10.18502/tim.v5i2.3627 | |
| Keywords | ||
| Adverse drug reaction; Herbal medicine; Infant; Newborn; Outcome; Pregnancy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
